IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Ardevora Asset Management LLP

Ardevora Asset Management LLP trimmed its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 52.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,883 shares of the company's stock after selling 12,011 shares during the quarter. Ardevora Asset Management LLP's holdings in IDEXX Laboratories were worth $6,041,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Valley National Advisers Inc. lifted its holdings in shares of IDEXX Laboratories by 84.6% during the 4th quarter. Valley National Advisers Inc. now owns 48 shares of the company's stock valued at $26,000 after buying an additional 22 shares during the period. OFI Invest Asset Management bought a new position in shares of IDEXX Laboratories during the 3rd quarter valued at $25,000. Venturi Wealth Management LLC lifted its holdings in shares of IDEXX Laboratories by 226.3% during the 4th quarter. Venturi Wealth Management LLC now owns 62 shares of the company's stock valued at $34,000 after buying an additional 43 shares during the period. Altshuler Shaham Ltd bought a new position in shares of IDEXX Laboratories during the 4th quarter valued at $26,000. Finally, Geo Capital Gestora de Recursos Ltd purchased a new stake in shares of IDEXX Laboratories in the 3rd quarter worth $28,000. 87.84% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on IDXX shares. The Goldman Sachs Group upped their price objective on IDEXX Laboratories from $500.00 to $650.00 and gave the stock a "buy" rating in a research note on Wednesday, January 17th. William Blair restated an "outperform" rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. JPMorgan Chase & Co. upped their price objective on IDEXX Laboratories from $600.00 to $630.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 6th. Barclays upped their price objective on IDEXX Laboratories from $605.00 to $655.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 6th. Finally, Piper Sandler lowered IDEXX Laboratories from an "overweight" rating to a "neutral" rating and set a $525.00 price target for the company. in a research note on Tuesday, January 30th. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $591.50.

Insider Activity at IDEXX Laboratories

In related news, CEO Jonathan Jay Mazelsky sold 12,000 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the transaction, the chief executive officer now directly owns 79,247 shares of the company's stock, valued at $45,377,624.67. The sale was disclosed in a filing with the SEC, which is accessible through this link. In other news, CFO Brian P. Mckeon sold 23,326 shares of IDEXX Laboratories stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total transaction of $13,296,053.26. Following the completion of the sale, the chief financial officer now directly owns 29,718 shares in the company, valued at $16,939,557.18. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Jonathan Jay Mazelsky sold 12,000 shares of IDEXX Laboratories stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the sale, the chief executive officer now owns 79,247 shares of the company's stock, valued at $45,377,624.67. The disclosure for this sale can be found here. Insiders have sold a total of 43,524 shares of company stock valued at $24,871,960 over the last ninety days. 2.11% of the stock is owned by company insiders.

IDEXX Laboratories Trading Down 0.3 %

NASDAQ IDXX traded down $1.44 during trading on Friday, hitting $476.35. The stock had a trading volume of 568,646 shares, compared to its average volume of 376,960. The stock has a 50 day simple moving average of $538.02 and a 200 day simple moving average of $509.93. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.17 and a current ratio of 1.57. IDEXX Laboratories, Inc. has a one year low of $372.50 and a one year high of $583.39. The stock has a market capitalization of $39.56 billion, a price-to-earnings ratio of 47.30, a P/E/G ratio of 3.67 and a beta of 1.26.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its quarterly earnings results on Monday, February 5th. The company reported $2.32 earnings per share for the quarter, beating the consensus estimate of $2.12 by $0.20. IDEXX Laboratories had a net margin of 23.08% and a return on equity of 71.66%. The firm had revenue of $901.60 million during the quarter, compared to the consensus estimate of $891.88 million. During the same quarter in the previous year, the firm posted $2.05 earnings per share. The company's revenue was up 8.8% on a year-over-year basis. Sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.15 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.